NasdaqGS:MRNABiotechs
Does Moderna’s (MRNA) New Board Appointment Hint At A Shift In Capital Allocation Priorities?
Earlier this week, Moderna announced that veteran finance executive Michael McDonnell, former Biogen CFO, joined its Board as a Class II director and Audit Committee member, while David Rubenstein shifted from the Audit Committee to the Nominating and Corporate Governance Committee.
His addition brings decades of public-company financial leadership in life sciences and technology, potentially sharpening Moderna’s oversight of capital allocation, risk management, and commercialization plans...